University Of Heidelberg Medical Center

This phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma achieve deeper remission and live longer without the cancer progressing. About 662 participants will receive either standard therapy or standard th…